Andy Sassine
Known title: Chief Financial OfficerCIK: 0001515322
Andy Sassine's purchase track record
Andy Sassine has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/15/2025 | ARCT | $20K | -62.7% | -63.0% | +6.0% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ARCT | ▲ Buy | Open Market | 1,238 | $20K | 8/15/2025 | View on chart |
| ARCT | ▼ Sell | Open Market | 50,000 | $1.6M | 6/12/2024 | View on chart |
| ARCT | ▲ Buy | Grant | 1,223 | $21K | 8/15/2023 | View on chart |
| ARCT | ▲ Buy | Grant | 1,068 | $20K | 8/15/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Arcturus Shares Rise on Phase II Data and Analyst Upgrades
Arcturus Therapeutics reported positive Phase II data for ARCT-810 and introduced a new over-the-counter therapy platform. These updates coincided with Citigroup upgrading the stock to Buy and raising its price target to $20. The company also discussed progress in its mRNA liver therapeutics platform, contributing to the recent share price movement.
Arcturus Shares Rise on Phase II Data and Analyst Upgrades. Arcturus Therapeutics reported positive Phase II data for ARCT-810 and introduced a new over-the-counter therapy platform. These updates coincided with Citigroup upgrading the stock to Buy and raising its price target to $20. The company also discussed progress in its mRNA liver therapeutics platform, contributing to the recent share price movement.